Back to Results
First PageMeta Content
Pseudobulbar affect / Dextromethorphan / Pseudobulbar palsy / Forward-looking statement / Government procurement in the United States / Neurochemistry / Pharmacology / Biochemistry


ソフトチーム検討事項
Add to Reading List

Document Date: 2014-12-02 20:01:04

Open Document

File Size: 1,42 MB

Share Result on Facebook

City

Aliso Viejo / /

Company

Transaction & Avanir Pharmaceuticals / Avanir Pharmaceuticals Tatsuo Higuchi / Otsuka / Otsuka Pharmaceutical / Avanir Pharmaceuticals / Bigarade Corporation / Lidak Pharmaceuticals / /

Country

United States / /

Currency

USD / /

Event

FDA Phase / Name Change / Debt Financing / M&A / /

IndustryTerm

bank loan / pharmaceutical industry / owned subsidiary / indirect subsidiary / healthcare cost containment / therapeutic products / foreign healthcare reforms / /

MedicalCondition

Lou Gehrig's disease / Alzheimer’s disease / dementia / disease / Alzheimer‘s disease / ALS / migraine / dementias / neurological disease / especially neurological disease / Parkinson's disease / traumatic brain injury / psychiatric disease / multiple sclerosis / disorder / CNS Discovery Research Clinical development Launch Marketing Avanir’s neurological disease / injuries / disorders / /

Organization

U.S. Securities and Exchange Commission / Securities and Exchange Commission / /

Person

Lou Gehrig / /

Position

Governor / Director / CEO / President & Representative / /

Product

Sigma / AVP-825 / NUEDEXTA® / /

ProvinceOrState

California / /

Technology

drug discovery / drug development / /

URL

www.sec.gov / www.pbafacts.com / /

SocialTag